Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $39.81.

A number of research analysts have issued reports on TNDM shares. Barclays reduced their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Royal Bank of Canada dropped their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Stifel Nicolaus reduced their target price on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Sanford C. Bernstein downgraded Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Robert W. Baird decreased their target price on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a report on Thursday, May 1st.

Tandem Diabetes Care Stock Performance

TNDM stock opened at $21.29 on Tuesday. The stock's 50 day simple moving average is $18.56 and its 200 day simple moving average is $28.43. Tandem Diabetes Care has a 12-month low of $15.75 and a 12-month high of $53.69. The firm has a market cap of $1.42 billion, a P/E ratio of -11.03 and a beta of 1.47. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. During the same quarter in the previous year, the business posted ($0.65) earnings per share. The company's quarterly revenue was up 22.3% compared to the same quarter last year. As a group, equities research analysts predict that Tandem Diabetes Care will post -1.68 EPS for the current year.

Insider Buying and Selling

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Tandem Diabetes Care

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Hood River Capital Management LLC bought a new stake in Tandem Diabetes Care in the 4th quarter valued at $46,035,000. Jacobs Levy Equity Management Inc. lifted its stake in shares of Tandem Diabetes Care by 189.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock valued at $59,830,000 after buying an additional 1,086,337 shares during the period. Brown Advisory Inc. acquired a new stake in Tandem Diabetes Care during the fourth quarter worth about $32,889,000. GW&K Investment Management LLC grew its position in Tandem Diabetes Care by 34.9% during the first quarter. GW&K Investment Management LLC now owns 2,863,987 shares of the medical device company's stock worth $54,874,000 after buying an additional 740,499 shares in the last quarter. Finally, Park West Asset Management LLC increased its stake in Tandem Diabetes Care by 49.5% during the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after acquiring an additional 530,000 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.